Measles Vaccine-Associated Rash Illness in China: an Emerging Issue in the Process of Measles Elimination.


Journal

Journal of clinical microbiology
ISSN: 1098-660X
Titre abrégé: J Clin Microbiol
Pays: United States
ID NLM: 7505564

Informations de publication

Date de publication:
21 10 2020
Historique:
received: 12 06 2020
accepted: 24 08 2020
pubmed: 4 9 2020
medline: 24 6 2021
entrez: 4 9 2020
Statut: epublish

Résumé

Along with the implementation of measles case-based surveillance, measles vaccine-associated rash illness (VARI) cases were detected in China. To better understand the characteristics of VARI, 101 VARI cases confirmed by measles virus genotyping in 2011 to 2018 were analyzed in this study. With the decrease in measles incidence, the detection rate of VARI cases increased among the cases confirmed by genotyping. Compared with genotype H1 wild-type measles, VARI occurred throughout the year, without obvious seasonal distribution. Infants and children of ages 8 to 23 months were the main population of VARI. VARI mainly occurred within 14 days after measles vaccination. The number of VARI cases peaked on the 8th day after measles vaccination, which was later than that of genotype H1 wild-type measles cases with a measles vaccination history. VARI presents clinical symptoms similar to those of measles. The frequencies of the "3Cs" (cough, coryza, and conjunctivitis), Koplik spots, and complications in VARI cases were significantly lower than those in wild-type measles cases. In total, 94.06% of sequences from VARI cases were identical to measles vaccine strain S191 in the C-terminal 450-nucleotide sequence of the nucleoprotein (N-450) gene. A few substitutions were found in N-450 sequences of the VARI cases. The confirmation of VARI has become an emerging issue in the process of measles elimination. Rapid confirmation of VARI is critical for measles surveillance and will help to determine the response measures for measles, especially in measles preelimination and elimination settings. The suspected measles cases with measles-containing vaccine (MCV) vaccination were recommended to be tested by the laboratory to identify wild-type measles or VARI.

Identifiants

pubmed: 32878947
pii: JCM.01472-20
doi: 10.1128/JCM.01472-20
pmc: PMC7587102
pii:
doi:

Substances chimiques

Measles Vaccine 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2020 American Society for Microbiology.

Références

Microbiol Immunol. 2013 Mar;57(3):246-51
pubmed: 23489085
Wkly Epidemiol Rec. 2012 Mar 2;87(9):73-81
pubmed: 22462199
PLoS One. 2019 Jun 20;14(6):e0218782
pubmed: 31220172
Wkly Epidemiol Rec. ;92(17):205-27
pubmed: 28459148
Bull World Health Organ. 2014 May 1;92(5):340-7
pubmed: 24839323
J Med Virol. 2016 Nov;88(11):1867-73
pubmed: 27089242
Int Health. 2017 May 1;9(3):184-189
pubmed: 28582561
J Microbiol Immunol Infect. 2017 Oct;50(5):578-585
pubmed: 26698687
Emerg Infect Dis. 2010 Jun;16(6):943-7
pubmed: 20507744
Jpn J Infect Dis. 2014;67(3):180-3
pubmed: 24858606
Zhongguo Yi Miao He Mian Yi. 2009 Aug;15(4):310-5
pubmed: 20077727
Vaccine. 2020 Feb 28;38(10):2361-2367
pubmed: 32037227
J Infect Dis. 2011 Jul;204 Suppl 1:S514-23
pubmed: 21666208
J Med Virol. 2002 Aug;67(4):596-602
pubmed: 12116010
Lancet Glob Health. 2019 Mar;7(3):e313-e320
pubmed: 30784632
Vaccine. 2016 May 17;34(23):2531-6
pubmed: 27083423
Wkly Epidemiol Rec. 2015 Jul 24;90(30):373-80
pubmed: 26211016
Clin Infect Dis. 2020 Feb 18;:
pubmed: 32067029
J Clin Microbiol. 2017 Mar;55(3):735-743
pubmed: 27852670
J Clin Microbiol. 2018 Jul 26;56(8):
pubmed: 29743309
Clin Microbiol Infect. 2014 Sep;20(9):O566-77
pubmed: 24438091
J Clin Virol. 2013 Sep;58(1):176-82
pubmed: 23806666
J Med Virol. 2009 Aug;81(8):1477-83
pubmed: 19551837
Virus Res. 1994 Mar;31(3):317-30
pubmed: 8191786
Viral Immunol. 2018 Mar;31(2):86-95
pubmed: 29256824
Vaccine. 2020 May 8;38(22):3832-3838
pubmed: 32280040

Auteurs

Aili Cui (A)

WHO WPRO Regional Reference Laboratory of Measles/Rubella and NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.

Huiling Wang (H)

WHO WPRO Regional Reference Laboratory of Measles/Rubella and NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.

Zhen Zhu (Z)

WHO WPRO Regional Reference Laboratory of Measles/Rubella and NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.

Naiying Mao (N)

WHO WPRO Regional Reference Laboratory of Measles/Rubella and NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.

Jinhua Song (J)

WHO WPRO Regional Reference Laboratory of Measles/Rubella and NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.

Yan Zhang (Y)

WHO WPRO Regional Reference Laboratory of Measles/Rubella and NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China zhangyan9876543@163.com wenbo_xu1@aliyun.com.

Wenbo Xu (W)

WHO WPRO Regional Reference Laboratory of Measles/Rubella and NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China zhangyan9876543@163.com wenbo_xu1@aliyun.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH